SCHEMBL7128316

SCHEMBL7128316

CC(C(=O)NS(=O)(=O)CCC(=O)OCc1ccccc1)c1ccc(C(=O)c2ccccc2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.49
MAOA P21397 1/20 0.49
ADRA1A P35348 1/20 0.49
DRD3 P35462 1/20 0.49
KCNH2 Q12809 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
CYP2C19 P33261 1/20 0.49
LMNA P02545 2/20 0.42
UCHL5 Q9Y5K5 2/20 0.37
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
CA1 P00915 4/20 0.34
CA2 P00918 4/20 0.34
ACHE P22303 3/20 0.34
MAPK1 P28482 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285807 0.87 ADRA2C (0.47) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL6284421 0.81 HPGD (0.57) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL27547914 0.80 PTGS1 (0.52) CYP1A2CYP3A4CYP2D6CYP2C9HPGD
SCHEMBL7159171 0.80 PTGS1 (0.52) CYP1A2CYP3A4CYP2D6CYP2C9HPGD
SCHEMBL27568101 0.80 HPGD (0.53) CYP2C9HPGDLMNAALDH1A1KMT2A
SCHEMBL6330554 0.75 CXCR1 (0.55) CYP2C9LMNAMAPK1
SCHEMBL7779067 0.75 CXCR1 (0.55) CYP2C9LMNAMAPK1
SCHEMBL27568093 0.75 HPGD (0.44) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL7116994 0.74 LMNA (0.39) HPGDLMNAALDH1A1KMT2ACA1
SCHEMBL6284426 0.74 HPGD (0.61) ADRA2CMAOAADRA1ADRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
CN-1324344-A N- (2-aryl-propionyl) -sulfonamides and pharmaceutical compositions containing them DOMPE SPA (IT) 2001-11-28 CN disclosed
EP-1123276-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Dompe' S.P.A. (IT) 2001-08-16 EP disclosed
WO-2000024710-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 ADRA2C 1739/4885MAOA 3259/4885ADRA1A 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.